About Us

About us

Restoring health to GI tissues

Curileum Discovery Ltd is a biotechnology company based adjacent to St Mark’s Hospital in London, one of the world’s only gastrointestinal (GI)-dedicated hospitals. Backed by over 40 years of drug discovery, we focus on developing novel therapies that restore the health of GI tissues, intervening early in disease development to prevent coloreactla cancer and treat inflammatory bowel disease (IBD).

Colorectal cancer is the second leading cause of cancer deaths worldwide, costing the NHS over £1 billion annually in the UK. Intervening early saves lives and reduces costs of monitoring and treatment[1, 2].

Our team discovered and is developing a novel, oral pan-PPAR agonist drug – ULI262 – that addresses the root cause of bowel cancer: abnormal cell production driving polyp formation and progression to cancer.

Curileum is guided by an experienced team of scientific and clinical advisors. Our founder and CEO, Dr Jeff Moore, has worked at the forefront of research into the regulation of cell production throughout his career. Dr Moore previously led the discovery and development of a novel protein that protected the bone marrow and GI tract from the toxicity of chemotherapy, including raising over $20m. 

We are raising $20m for a first-in-human clinical study in FAP patients starting in 2027. The company’s drug development team, supported by its scientific and clinical advisory boards, is on track to optimise ULI262’s chemical synthesis, scale up drug production, complete preclinical pharmacology and toxicity studies, and prepare regulatory documentation for a Clinical Trial Application. We expect the FDA will grant Orphan Drug Designation for the treatment of FAP, helping to expedite the clinical trial process and accelerate the timeline to treating patients in urgent need. 
 
Please contact us to discuss potential investment opportunities.

1 https://www.ncbi.nlm.nih.gov/books/NBK580741/
2 https://www.ncbi.nlm.nih.gov/books/NBK580741/